Find Print
0 Find synonyms

Find synonyms Find exact match

What's new in dermatology
Official reprint from UpToDate® ©2017 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
What's new in dermatology
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Jan 2017. | This topic last updated: Feb 17, 2017.

The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.


Relationship between acne and low-fat or skim milk consumption (August 2016)

Several studies have reported associations between dairy consumption and acne. A new case-control study used three 24-hour diet recall phone interviews to evaluate dietary intake, validated software for data collection, and dermatologist assessment of acne severity [1]. An association was found between acne and higher consumption of low-fat or skim milk, comparing 120 teenagers with moderate facial acne and 105 teenagers without acne. There was no association for full fat milk. Although this study supports a relationship between acne and low-fat or skim milk consumption, further study is needed before specific dietary recommendations can be made for patients with acne. (See "Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Diet'.)


Topical crisaborole for atopic dermatitis (December 2016)

A topical preparation containing 2% crisaborole, an investigational boron-based, small-molecule, phosphodiesterase-4 inhibitor, was approved by the US Food and Drug Administration in December 2016 for the treatment of mild to moderate atopic dermatitis in patients two years of age and older [2]. In four-week clinical trials, topical crisaborole was more effective than placebo in reducing pruritus, skin inflammation, excoriation, and lichenification. However, trials comparing topical crisaborole with other topical treatments for atopic dermatitis are lacking. (See "Treatment of atopic dermatitis (eczema)", section on 'Crisaborole'.)

Investigational topical tofacitinib for atopic dermatitis (November 2016)

Tofacitinib is a small-molecule JAK kinase inhibitor that is currently available as an oral therapy for rheumatoid arthritis. An investigational topical preparation was compared with placebo in a randomized trial of 69 adult patients with mild to moderate atopic dermatitis, treated for four weeks [3]. Compared with those receiving placebo, subjects receiving tofacitinib showed greater improvements in eczema area and severity scores, were more likely to be assessed by physicians as clear or almost clear, and tolerated the drug well. Larger studies of longer duration are needed to evaluate long-term efficacy and safety. (See "Treatment of atopic dermatitis (eczema)", section on 'Tofacitinib'.)

Persistence of pediatric atopic dermatitis (November 2016)

Atopic dermatitis (AD) is a chronic disease with a highly variable course. Although most children are thought to “outgrow” it before adolescence, little is known about the factors associated with its persistence into adulthood. A meta-analysis including over 110,000 subjects found that 20 percent of children with AD had persistent disease eight years after the diagnosis, and less than 5 percent had persistent disease 20 years later [4]. Children who developed AD before two years of age had a much lower risk of persistent disease than those who developed AD later in childhood or during adolescence. Other predictors of persistent AD were severity and duration of AD and female sex, whereas hypersensitivity to one or more allergens at disease onset did not seem to influence the persistence of disease. (See "Pathogenesis, clinical manifestations, and diagnosis of atopic dermatitis (eczema)", section on 'Clinical course and complications'.)

Dupilumab for moderate to severe atopic dermatitis in adults (October 2016)

Two 16-week phase III trials of identical design, including nearly 1400 adults, evaluated the efficacy of dupilumab, an investigational monoclonal antibody that targets interleukin 4 and 13, for the treatment of atopic dermatitis not controlled by topical therapies [5]. The primary end point was the proportion of patients to achieve a "clear" or "almost clear" rating, which occurred in approximately 40 and 10 percent of patients receiving dupilumab and placebo, respectively. The drug was well tolerated. Dupilumab is not yet available for clinical use. (See "Treatment of atopic dermatitis (eczema)", section on 'Dupilumab'.)

Investigational topical therapy for atopic dermatitis (September 2016)

Crisaborole is a topical boron-based phosphodiesterase-4 inhibitor with limited systemic absorption, which is under investigation as a novel topical therapy for atopic dermatitis. In two identical, multicenter randomized trials, a total of 1522 patients ≥2 years old with mild to moderate atopic dermatitis were treated with crisaborole 2% ointment or vehicle twice daily for 28 days [6]. More patients in the crisaborole groups than in the vehicle groups achieved the primary end point (an investigator’s global assessment score of 0 [clear] or 1 [almost clear] with a two-grade or more improvement from baseline). Improvement was noted in pruritus, skin inflammation, excoriation, and lichenification. Crisaborole-related adverse events occurred in 4.4 percent of patients and were mild and limited to burning or stinging at the site of application. Although crisaborole appears a promising nonsteroidal topical treatment for mild to moderate atopic dermatitis, studies of longer duration than four weeks are needed to evaluate its efficacy and safety. (See "Treatment of atopic dermatitis (eczema)".)


Management of microvascular damage in systemic sclerosis (December 2016)

Vasoactive drugs are used for systemic sclerosis (SSc) patients with severe Raynaud phenomenon (RP) and digital ulcers. For prevention of recurrent digital ulcers, there may be a benefit from combination therapy with intravenous iloprost and bosentan. In a prospective observational study with 30 SSc patients receiving intravenous iloprost for severe secondary RP, half of the patients were also given bosentan following the development of digital ulcers or pulmonary arterial hypertension [7]. After four years of follow-up, the iloprost plus bosentan group showed evidence of a significant improvement in digital microvasculature structure and function, which also corresponded with a significant reduction in the incidence of new digital ulcers. This limited study needs confirmation but suggests that combination therapy may be helpful in complex SSc patients with recurrent digital ulcers. (See "Treatment of the Raynaud phenomenon resistant to initial therapy", section on 'Recurrent digital ulcers in systemic sclerosis'.)

Tofacitinib for alopecia areata (December 2016)

Support is increasing for the use of tofacitinib, a small molecule selective Janus kinase 1/3 inhibitor, for alopecia areata. A retrospective study of long-term treatment with tofacitinib (with or without adjuvant prednisone) in 90 adults with severe alopecia areata (at least 40 percent scalp hair loss, alopecia totalis, or alopecia universalis) found that over one-half of the 65 patients with a duration of the current disease episode of ≤10 years achieved greater than 50 percent improvement in the Severity of Alopecia Tool [SALT] score, without serious adverse effects [8]. Although these findings suggest benefit of tofacitinib for alopecia areata, controlled trials are needed to confirm efficacy and safety. (See "Management of alopecia areata", section on 'Janus kinase inhibitors'.)

Guidelines for the treatment of systemic sclerosis (October 2016)

The British Society for Rheumatology (BSR) and the British Health Professionals in Rheumatology (BHSR) have published a comprehensive set of guidelines for the management of systemic sclerosis (SSc) [9]. Some of the key points include the importance of making an early diagnosis and considering treatment with an immunosuppressive agent in patients with diffuse cutaneous SSc of less than three years' duration. They also review the major therapies for treating organ-based disease and emphasize the importance of referring patients to specialty centers with access to multidisciplinary care. (See "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'General principles of management'.)

Screening and prevention of hydroxychloroquine retinopathy (August 2016)

Antimalarial agents hydroxychloroquine (HCQ) and chloroquine are widely used for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and other inflammatory and dermatologic conditions, and are generally thought to be safe. Retinal toxicity is a known risk, however, and measures to minimize this potential toxicity are necessary. Recently, the American Academy of Ophthalmology issued revised recommendations for screening and prevention of retinopathy [10]. Key changes include the following:

The maximum daily dose of HCQ should not exceed 5 mg/kg (previously 6.5 mg/kg), and the maximum daily dose of chloroquine should not exceed 2.3 mg/kg (previously 3 mg/kg).

Real body weight should be used to calculate dose limits instead of ideal body weight.

In addition to exceeding the recommended daily dose, major risk factors for retinal toxicity include antimalarial use for greater than five years, renal disease, concomitant tamoxifen use, and the presence of macular disease. All patients should undergo a baseline eye examination before or within a year of beginning treatment with an antimalarial drug and, if normal, at least annually after five years of exposure for patients without major risk factors. For the treatment of rheumatic diseases, we typically use standard daily doses of HCQ (non-weight-based, eg, up to 400 mg) in individuals weighing 80 kg or more. In patients weighing less than 80 kg, we use a lower daily dose of HCQ up to the maximum of 5 mg/kg of real body weight. (See "Antimalarial drugs in the treatment of rheumatic disease", section on 'Ocular health'.)


Subcutaneous methotrexate for plaque psoriasis (January 2017)

Although methotrexate is a common treatment for psoriasis, data supporting its use are limited. In a randomized trial of 120 patients with moderate to severe plaque psoriasis, those treated with subcutaneous methotrexate for 16 weeks achieved a 75 percent improvement in the Psoriasis Area and Severity Index score more frequently than those receiving placebo (41 versus 10 percent) [11]. Treatment was generally well tolerated. These data support methotrexate as a treatment option for psoriasis. (See "Treatment of psoriasis", section on 'Methotrexate'.)

Haplotype may predict response to tonsillectomy in chronic plaque psoriasis (November 2016)

Tonsillectomy leads to clinical improvement in some patients with chronic plaque psoriasis, although surgery carries risk, and a reliable predictor of which patients are most likely to respond is lacking. A prospective cohort study of 28 patients with moderate to severe chronic plaque psoriasis and a history of psoriasis exacerbations in association with sore throat and/or streptococcal throat infections suggests that HLA-Cw*0602 homozygotes may derive greater benefit from tonsillectomy than HLA-Cw*0602 heterozygotes and HLA-Cw*0602-negative patients [12]. Additional study is necessary to confirm this finding given the small size of the study. (See "Treatment of psoriasis", section on 'Tonsillectomy'.)

Secukinumab versus ustekinumab for moderate to severe plaque psoriasis (September 2016)

Previous data from the CLEAR trial, a randomized trial that compared secukinumab to ustekinumab for moderate to severe plaque psoriasis, demonstrated superiority of secukinumab over a treatment period of 16 weeks. An analysis of 52-week data from the CLEAR trial shows sustained superiority of secukinumab with continued treatment [13]. At week 52, 76 percent of patients in the secukinumab group achieved at least 90 percent improvement in the Psoriasis Area and Severity Index score compared with 61 percent in the ustekinumab group. In addition, secukinumab was associated with greater improvement in health-related quality of life. Safety was comparable between the two groups. (See "Treatment of psoriasis", section on 'Secukinumab'.)


Association of vitiligo with hematopoietic stem cell transplantation (February 2017)

Previous reports suggested that recipients of hematopoietic stem cell transplantation (HSCT) have an increased risk of developing vitiligo. In a Korean nationwide population study including approximately 2700 HSCT recipients and 8200 controls, HSCT recipients had a threefold increased risk of developing vitiligo [14]. Risk factors included receipt of an allogeneic versus autologous graft and stem cells derived from the bone marrow rather than peripheral blood. Although the pathogenetic mechanisms underlying the development of vitiligo in HSCT recipients are unclear, they may include adoptive transfer of vitiligo from donor, immunosuppression associated with preparative regimens, or chronic graft-versus-host disease. Clinicians should counsel patients undergoing HSCT regarding the risk of vitiligo. (See "Vitiligo: Pathogenesis, clinical features, and diagnosis", section on 'Etiology'.)

Topical therapy for pyoderma gangrenosum (November 2016)

Pyoderma gangrenosum (PG) can be challenging to treat and often exhibits prolonged healing times. Topical therapy is commonly used for the treatment of mild PG; however, efficacy data have been limited. In the largest prospective cohort study to assess topical treatments for PG, 66 patients received either clobetasol propionate, tacrolimus, or other topical therapies [15]. The majority of patients (74 percent) received clobetasol propionate. By six months, 44 percent of patients receiving topical therapy achieved ulcer healing. These results provide support for the use of topical therapies. (See "Pyoderma gangrenosum: Treatment and prognosis", section on 'Local corticosteroids'.)

Adalimumab for hidradenitis suppurativa (August 2016)

Hidradenitis suppurativa, also known as acne inversa, is often challenging to treat. Two similar phase III randomized trials (PIONEER I [n = 307] and PIONEER II [n = 326]) support the efficacy of adalimumab for moderate to severe hidradenitis suppurativa [16]. After 12 weeks, more patients assigned to the adalimumab groups achieved a clinical response (≥50 percent reduction in the total abscess and inflammatory nodule count with no increase in the abscess or draining fistula count) compared with the placebo groups (42 versus 26 percent in PIONEER I and 59 versus 28 percent in PIONEER II). Rates of serious adverse events were similar between the adalimumab and placebo groups. These findings support adalimumab as a treatment option for moderate to severe hidradenitis suppurativa. Improvement, however, is generally only partial. (See "Hidradenitis suppurativa (acne inversa): Treatment", section on 'TNF-alpha inhibitors'.)

Use of UpToDate is subject to the Subscription and License Agreement.


  1. LaRosa CL, Quach KA, Koons K, et al. Consumption of dairy in teenagers with and without acne. J Am Acad Dermatol 2016; 75:318.
  2. (Accessed on December 20, 2016).
  3. Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 2016; 175:902.
  4. Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): A systematic review and meta-analysis. J Am Acad Dermatol 2016; 75:681.
  5. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016; 375:2335.
  6. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016; 75:494.
  7. Trombetta AC, Pizzorni C, Ruaro B, et al. Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis. J Rheumatol 2016; 43:2033.
  8. Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol 2017; 76:22.
  9. Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford) 2016; 55:1906.
  10. Marmor MF, Kellner U, Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016; 123:1386.
  11. Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2016.
  12. Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. HLA-Cw6 homozygosity in plaque psoriasis is associated with streptococcal throat infections and pronounced improvement after tonsillectomy: A prospective case series. J Am Acad Dermatol 2016; 75:889.
  13. Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol 2017; 76:60.
  14. Bae JM, Choi KH, Jung HM, et al. Subsequent vitiligo after hematopoietic stem cell transplantation: A nationwide population-based cohort study from Korea. J Am Acad Dermatol 2016.
  15. Thomas KS, Ormerod AD, Craig FE, et al. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. J Am Acad Dermatol 2016; 75:940.
  16. Kimball AB, Okun MM, Williams DA, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med 2016; 375:422.
Topic 87552 Version 7024.0

Topic Outline


All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.